PULSE BIOSCIENCES, INC.
For the period ended Dec 31, 2025. Filed Feb 19, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 19, 2026
PLSE$55.12-5.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations and Comprehensive Loss
(in thousands, except share and per share data)
| Year Ended December 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Revenue: | ||
| Product revenue | $350 | $— |
| Cost and expenses: | ||
| Cost of product revenue | 539 | — |
| Research and development | 44,721 | 32,336 |
| Selling, general and administrative | 32,029 | 23,921 |
| Total cost and expenses | 77,289 | 56,257 |
| Loss from operations | (76,939) | (56,257) |
| Other income (expense): | ||
| Interest income | 4,210 | 2,690 |
| Other expense | (52) | (18) |
| Total other income | 4,158 | 2,672 |
| Net loss | (72,781) | (53,585) |
| Comprehensive loss | $(72,781) | $(53,585) |
| Net loss per share, basic and diluted | $(1.08) | $(0.92) |
| Weighted average common shares outstanding, basic and diluted | 67,395,339 | 58,397,597 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.